A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment
A phase 3 trial of Docetaxel in gastric & gastro-oesophageal junction cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.
Overview
A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment is a phase 3 interventional study registered as NCT07518147 by Sichuan Baili Pharmaceutical Co., Ltd., with 438 participants planned, started 2026-05-15 and due to reach its primary completion in 2029-12. Interventions recorded: BL-M05D1, Paclitaxel, Docetaxel and Irinotecan hydrochloride.
Similar pages
not linked directly; found by shared links- TrialA Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma(PANKU-Bladder01)
Shares SystImmune / Sichuan Biokin, Docetaxel and the tag pipeline.
- TrialKN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy
Shares Docetaxel, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialA Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer
Shares Docetaxel, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialA Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors
Shares SystImmune / Sichuan Biokin and the tag pipeline.
- TrialA Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary System Tumors
Shares SystImmune / Sichuan Biokin and the tag pipeline.
- TrialA Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies
Shares SystImmune / Sichuan Biokin and the tag pipeline.
- TrialA Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumors
Shares SystImmune / Sichuan Biokin and the tag pipeline.
- TrialA Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer
Shares SystImmune / Sichuan Biokin and the tag pipeline.